Contact information
Type
Scientific
Primary contact
Dr Julia Mayerle
ORCID ID
Contact details
Universitätsmedizin Greifswald
Klinik und Poliklinik für Innere Medizin A
Friedrich-Loeffler-Straße 23a
Greifswald
17475
Germany
+49 383 486 7244
EUROPAC-2@uni-greifswald.de
Additional identifiers
EudraCT number
2006-000087-83
ClinicalTrials.gov number
NCT00142233
Protocol/serial number
N/A
Study information
Scientific title
Double blind randomised controlled trial to investigate the efficacy of ANTOX (version 1.2) and MGCT (Magnesium) for the treatment of hereditary and idiopathic chronic pancreatitis
Acronym
EUROPAC-2
Study hypothesis
In patients with chronic pancreatitis, pain can be reduced significantly by a treatment with ANTOX (version 1.2) or Magnesium (MGCT) compared to the control group.
Ethics approval
Approval received from the following local ethics committees:
1. Germany:
1.1. Greifswald (date: 16th April 2004, ref: III-UV-92-03)
1.2. Heidelberg (date: 12th December 2005, ref: 325-2005)
1.3. Hamburg (date: 11th May 2005, ref: M-135/05)
1.4. Muenster (date: 11th May 2006, ref: AZ 2006-092-b-A)
1.5. Munich (date: 7th August 2006, ref: 193-06)
1.6. Leipzig (date: 17th July 2006, ref: 129-2006)
1.7. Kiel (date: 20th June 2006, ref: B 260/06)
1.8. Tuebingen (date: 14th March 2007, ref: 87-2007-G)
2. United Kingdom: Liverpool (date: 12th June 2006, since then they have put in an amendment [001] and have received approval for this on the 3rd April 2007, ref: 06/Q1502/4)
3. France: Clichy (date: 6th December 2010, ref. 2010-Nov.-12458)
Applications with the Ethics committee are under way at:
1. Austria: Vienna
2. Czech Republic: Brno
Study design
Randomised placebo-controlled three-armed trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Patient information can be found on the website at http://www.pancreas.de/ (only in German)
Condition
Hereditary or idiopathic chronic pancreatitis
Intervention
Current interventions as of 16/02/2012
Group 1:
Two ANTOX (version 1.2) tablets, three times daily; antioxidant treatment (daily):
1. 300 µg organic selenium
2. 720 mg vitamin C
3. 228 mg vitamin E
4. 2880 mg methionine
Group 2:
Two Magnesium-L-Aspartate-hydrochloride (MGCT) (Magnesio-card 2.5 mmol) tablets three times a day, total dose 15 mmol (365 mg/per day)
Group 3:
The same number of tablets as in groups one and two but placebo instead of active drug.
Children aged 5 to 9 years will take half the number of tablets per day. Duration of intervention is 48 weeks for each group.
As this trial started prior to the changes in the Good Clinical Practice (GCP) guidelines and EU 2002 guidelines are applicable, the main part of the trial held in Germany did not need and therefore did not name a sponsor. The University of Liverpool trials unit takes over responsibilities as a sponsor for the UK, and these are the details held below in the sponsor section.
Previous interventions
Group 1:
Two ANTOX (version 1.2) tablets, three times daily; antioxidant treatment (daily):
1. 300 µg organic selenium
2. 54000 IU beta-carotene = 18 mg
3. 750 mg vitamin C
4. 540 IU of vitamin E = 240 mg
5. 2700 mg methionine
Group 2:
Two Magnesium-L-Aspartate-hydrochloride (MGCT) (Magnesio-card 2.5 mmol) tablets three times a day, total dose 15 mmol (365 mg/per day)
Group 3:
The same number of tablets as in groups one and two but placebo instead of active drug.
Children aged 5 to 9 years will take half the number of tablets per day. Duration of intervention is 48 weeks for each group.
As this trial started prior to the changes in the Good Clinical Practice (GCP) guidelines and EU 2002 guidelines are applicable, the main part of the trial held in Germany did not need and therefore did not name a sponsor. The University of Liverpool trials unit takes over responsibilities as a sponsor for the UK, and these are the details held below in the sponsor section.
Intervention type
Drug
Phase
Not Specified
Drug names
ANTOX (version 1.2), Magnesium (MGCT)
Primary outcome measures
Reduction in the number of days of pancreatic pain during 12 continuous months of treatment
Secondary outcome measures
Current secondary outcome measures as of 16/02/2012:
1. Intensity of pain recorded using a score (0-10) where 0 is no pain and 10 is worst pain imaginable
2. Analgesic consumption assessed using morphine equivalents
3. The number of days spent in hospital due to painful exacerbations of pancreatitis or due to complications arising due to pancreatitis will be obtained from the patient. The clinician responsible for the care of the patient will independently verify this
4. Quality of life (QoL) including activities of daily living
Previous secondary outcomes
1. Intensity of pain recorded using a visual analogue score (0 to 10) where 0 is no pain and 10 is the worst pain imaginable; this will be recorded daily in a pain diary by the patient
2. Analgesic consumption assessed using pethidine equivalents; this will be recorded daily in the pain diary by self report (or in case of children by parents report)
3. The number of days spent in hospital due to painful exacerbations of pancreatitis or due to complications arising due to pancreatitis will be obtained from the patient. The clinician responsible for the care of the patient will independently verify this; hospital stays will be reported as Serious Adverse Events (SAE) and therefore recorded within 24 hours at the leading trial centre
4. Quality of Life (QoL) including activities of daily living, recorded every 12 weeks by self report
5. Inflammatory response and pancreatic activity measured at pre-defined time points and during symptomatic attacks of pancreatitis assessed by the pancreatic inflammation markers, urinary Trypsinogen Activation Peptide (TAP) and urinary amylase and the exocrine sufficiency marker, faecal elastase; this will be recorded every 12 weeks during the study visit
6. Oxidant stress as measured by urinary thiobarbituric acid, at fixed time points and during symptomatic attacks of pancreatitis; this will be recorded every 12 weeks
7. Changes in the urinary levels of magnesium, selenium and vitamin C; this will be recorded every 12 weeks
8. Data acquisition including markers of inflammatory response during acute attack of chronic pancreatitis
Overall trial start date
01/05/2005
Overall trial end date
01/10/2014
Reason abandoned
Eligibility
Participant inclusion criteria
Current inclusion criteria as of 16/02/2012:
1. Patients with pancreatitis diagnosed for at least one year
2. Patients who have provided written informed consent
3. Patients who are willing to be followed up regularly for at least one year
4. Patients who are able and willing to complete Quality of Life and Pain Assessment questionnaires
5. Patients who are able and willing to provide urine and faecal within two weeks of each study visit
6. Patients aged 5 to 65 years of age
7. Individuals with characteristic pancreatic pain that is either intermittent or continuous (two or more episodes during the last 12 months)
8. Patients with documented Hereditary Pancreatitis (HP), clinically defined or proven by gene mutations in the PRSS1 gene, or patients with Idiopathic Chronic Pancreatitis (ICP) and no mutations detected in the PRSS1 gene.
Current inclusion criteria as of 10/07/2007:
1. Patients with pancreatitis diagnosed for at least one year
2. Patients who are willing to be followed up regularly for at least one year
3. Patients aged 5 to 65 years of age
4. Individuals with characteristic pancreatic pain that is either intermittent or continuous (two or more episodes during the last 12 months)
5. Patients with documented Hereditary Pancreatitis (HP), clinically defined or proven by gene mutations in the PRSS1 gene, or patients with Idiopathic Chronic Pancreatitis (ICP) and no mutations detected in the PRSS1 gene.
Previous inclusion criteria:
1. Patients must have had pancreatitis diagnosed for at least one year
2. Patients must be willing to be followed up regularly for at least one year
3. Patients aged 5 to 40 years
4. Individuals must have characteristic pancreatic pain that is either intermittent or continuous (two or more episodes during the last 12 months)
Participant type
Patient
Age group
Not Specified
Gender
Not Specified
Target number of participants
240
Participant exclusion criteria
Current exclusion criteria as of 16/02/2012:
1. Patients that do not consent to be involved in the trial, or patients under the age of 16 whose parents/guardians do not consent for them to be involved in the trial
2. Patients or parents/guardians of underage patients, with learning disabilities or other cognitive or sensory impairments that would prevent adequate understanding of the study requirements
3. Patients who are currently receiving treatment with antioxidants or magnesium tablets or who have had such treatment within the last 3 months
4. Patients who are currently receiving treatment with oral hypoglycaemics or steroids or who have had such treatment within the last 3 months
5. Patients with renal failure (serum creatinine ≥ 200µmol/l)
6. Patients with atrio-ventricular-block
7. Serum triglyceride levels ≥ 1000mg/dl
8. Patients who are dependent on daily opiate analgesia (morphine or equivalent for more than 12 months)
9. Patients who have chronic hepatic failure, or serious impairment of pulmonary, cardiac, neurological or cerebral function
10. Patients who are participating in another drug trial
11. Patients who are pregnant
12. All men and women of reproductive potential unless using at least two types of contraceptive precautions, one of which must be a condom
13. Lactating mothers
14. Patients with any disorder that would prevent adequate absorption of the active treatment
15. Patients suffering from schizophrenia
16. Patients who smoke more than 20 cigarettes per day
17. Patient has had pancreatic surgery since their last attack of pancreatitis, or is planning to have elective pancreatic surgery within the trial duration
Current exclusion criteria as of 10/07/2007:
1. Patients that do not consent to be involved in the trial, or underage patients whose parents/guardians do not consent for them be involved in the trial
2. Patients or parents/guardians of underage patients, with learning disabilities or other cognitive or sensory impairments that would prevent adequate understanding of the study requirements
3. Patients who are currently receiving treatment with antioxidants or magnesium tablets or who have had such treatment within the last three months
4. Patients who are currently receiving treatment with oral hypoglycaemics or steroids or who have had such treatment within the last three months
5. Patients with renal failure (serum creatinine greater than or equal to 200 µg/l)
6. Patients with atrio-ventricular-block
7. Serum triglyceride levels greater than or equal to 1000 mg/dl
8. Patients who are dependent on daily opiate analgesia (morphine or equivalent) for more than 12 months
9. Patients who have chronic hepatic failure, or serious impairment of pulmonary, cardiac, neurological or cerebral function
10. Patients who are participating in another drug trial
11. Patients who are pregnant
12. Women of childbearing age who are not using contraception
13. Lactating mothers
14. Patients with any disorder that would prevent adequate absorption of the active treatment
15. Patients suffering from schizophrenia
16. Patients who smoke more than 20 cigarettes per day
Previous exclusion criteria:
1. Patients that do not consent to be involved in the trial, or whose parents do not consent for their children to be involved
2. Patients or guardians of underage patients, with learning disabilities or other cognitive or sensory impairments that would prevent adequate understanding of the study requirements
3. Patients who have had treatment for less than three months, or are currently receiving treatment with antioxidants or magnesium tablets
4. Patients who have had recent (less than three months), or are currently receiving treatment with oral hypoglycaemics or steroid treatment
5. Patients with renal failure (serum creatinine greater than or equal to 200 µg/l)
6. Patients with atrio-ventricular-block
7. Serum triglyceride levels greater than or equal to 1000 mg/dl
8. Patients under the age of 5 years or over the age of 40 years
9. Patients who are dependent on daily opiate analgesia (morphine or equivalent) for more than 12 months
10. Patients who have chronic hepatic failure, or serious impairment of pulmonary, cardiac, neurological or cerebral function
11. Patients who are participating in another drug trial
12. Patients who are pregnant
13. Women of childbearing age who are not using contraception
14. Lactating mothers
15. Any disorder that would prevent adequate absorption of the active treatment
Recruitment start date
01/05/2005
Recruitment end date
01/10/2014
Locations
Countries of recruitment
France, Germany, United Kingdom
Trial participating centre
Universitätsmedizin Greifswald
Greifswald
17475
Germany
Sponsor information
Organisation
The University of Liverpool Clinical Trials Unit (UK)
Sponsor details
Director of Research
Faculty of Medicine
University of Liverpool
Liverpool
L69 3GA
United Kingdom
Sponsor type
University/education
Website
Funders
Funder type
Other
Funder name
Investigator initiated trial in each study centre, without industrial sponsoring. Pharma Nord will be contributing towards the UK trial coordinator.
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary